Integrating New Advances into Community Oncology Practice

Breast Cancer

Faculty

Maryam Lustberg

MD, MPH

Yale School of Medicine, New Haven, Connecticut

Professor of Internal Medicine (Medical Oncology), Director, Center for Breast Cancer, Chief, Breast Medical Oncology

Faculty

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

Prostate Cancer

Faculty

Neeraj Agarwal

MD, FASCO

The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Medical Oncologist, Co-Director, Prostate Cancer Program, Harvard Cancer Consortium

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota, Minneapolis, Minnesota

Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation

Relapsed/Refractory Multiple Myeloma

Faculty

Sagar Lonial

MD, FACP, FASCO

Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Chair and Professor, Department of Hematology and Medical Oncology, Anne and Bernard Gray Family Chair in Cancer, Chief Medical Officer

Faculty

Paul G Richardson

MD

Dana-Farber Cancer Institute, Boston, Massachusetts

Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center

Harvard Medical School, Boston, Massachusetts

RJ Corman Professor of Medicine

Moderator

Neil Love

MD

Research To Practice

Miami, Florida

Additional faculty to be announced.

Join us on Saturday, October 17^th from 7:15 AM to 12:00 PM eastern time.

7:15 AM – 7:25 AM – Welcome, Introductions and Meeting Overview

7:25 AM – 9:40 AM – MODULE 1: Breast Cancer
Localized Hormone Receptor-Positive Breast Cancer; Initial Therapy for Metastatic Disease 
Relapsed/Refractory (R/R) HR-Positive Metastatic Breast Cancer 
HER2-Positive Breast Cancer 
Triple-Negative Breast Cancer 

9:40 AM – 10:00 AM – BREAK

10:00 AM – 11:00 AM – MODULE 2: Prostate Cancer
Hormonal Therapy for Prostate Cancer 
Other Therapeutic Strategies for Prostate Cancer 

11:00 AM – 12:00 PM – MODULE 3: Relapsed/Refractory (R/R) Multiple Myeloma
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for R/R MM 
Other Strategies for R/R MM 

12:00 PM – Meeting Adjourns

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

Breast Cancer 

• Evaluate recently presented clinical research findings to determine their effect on the current management of localized or metastatic breast cancer. 
• Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for hormone receptor (HR)-positive localized or metastatic breast cancer in order to appropriately counsel patients regarding the optimal clinical use of these agents. 
• Recognize the biological rationale for the development of agents targeting the PI3K/AKT/mTOR pathway, and recognize available data with FDA-approved treatments for patients with HR-positive metastatic breast cancer (mBC) with and without PIK3CA/AKT1/PTEN alterations. 
• Understand the mechanism of action of, published research findings with and current and future clinical role of oral selective estrogen receptor degraders (SERDs) alone and in combination with other agents for patients with HR-positive mBC harboring ESR1 mutations. 
• Analyze the scientific justification for, available data with and potential clinical role of oral SERDs as adjuvant treatment for localized estrogen receptor-positive, HER2-negative breast cancer. 
• Evaluate published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for HER2-positive localized and metastatic breast cancer. 
• Review published research data supporting the use of chemotherapy or antibody-drug conjugate (ADC) therapy in combination with anti-PD-1/PD-L1 antibodies for localized or metastatic triple-negative breast cancer, and use this information to make appropriate treatment recommendations. 
• Interrogate published Phase III research findings documenting the efficacy of TROP2-directed ADC monotherapy for mBC to determine the current clinical applicability of this approach. 
• Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer. 

Prostate Cancer 

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients considering the potential benefits and risks of new and established forms of hormonal therapy. 
• Evaluate the biological rationale for and available data with perioperative androgen deprivation therapy in combination with an androgen receptor (AR) pathway inhibitor for high-risk localized or locally advanced prostate cancer, and review the potential clinical role of this novel strategy. 
• Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options. 
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms. 
• Assess the available research database supporting the use of PARP inhibitors in combination with AR pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms. 
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency. 
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies. 
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation. 

Relapsed/Refractory (R/R) Multiple Myeloma (MM) 

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for R/R MM. 
• Develop an understanding of the current clinical research database with various chimeric antigen receptor T-cell therapy platforms in the management of R/R MM in order to optimally integrate this novel therapeutic strategy into current treatment algorithms. 
• Assess available research data with B-cell maturation antigen (BCMA) and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms. 
• Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed ADC therapy for R/R MM. 
• Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research efforts evaluating cereblon E3 ligase modulators to prepare for the potential clinical availability of these agents for patients with R/R MM. 
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM. 
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients.

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 4.25 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statement
This educational activity for 4.25 contact hours is provided by Research To Practice.

This activity is awarded 4.25 ANCC pharmacotherapeutic contact hours.

ONCC/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be remitted for ONCC/ILNA approval.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.0425 CEU (4.25 contact hours) of continuing education credit. To receive 4.25 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Dr Agarwal has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Antonarakis — Advisory Committees: Abeona Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus, Vir Biotechnology Inc; Consulting Agreements: Acerand Therapeutics, Blue Earth Diagnostics, Boundless Bio, Clarivate, Clearview Healthcare Partners, Curium, DAVA Oncology, EcoR1 Capital LLC, Global Life Sciences Alliance, Health Monitor Network, Johnson & Johnson, Lilly, Lumanity, Propella Therapeutics Inc, Slingshot Insights, Third Bridge, Z-Alpha; Contracted Research: Actinium Pharmaceuticals Inc, MacroGenics Inc, Merck, MorphoSys, Novartis, Orion Corporation, pharmaand GmbH, Seagen; Patents: Qiagen; Nonrelevant Financial Relationships: Binaytara Foundation, Conexiant, eCancer, Fred Hutch Cancer Center, MJH Life Sciences, Targeted Oncology, The Medical Educator Consortium. Dr Lonial — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc. Dr Lustberg — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Sandoz Inc, a Novartis Division; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP. Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics. Dr Richardson — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Karyopharm Therapeutics, Oncopeptides. Additional faculty to be announced.

MODERATOR
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, GSK, Johnson & Johnson, Kite, A Gilead Company, Novartis, and Puma Biotechnology Inc.

The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Parkway
Orlando, FL 32837
Hotel Phone: (407) 206-2400

Meeting Room
Tuscany Ballroom (Salons D-H) — Lobby Level

Hotel Room Reservations

• Florida Cancer Specialists (FCS) members, please be sure to book accommodations in the FCS room block.
• For all other registrants, room reservation information will be included with the confirmation email after you have registered for this program.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.